1759-7706

Thoracic Cancer

Wiley (Blackwell Publishing)

View prefix report (10.1111)

Health Score

0 Excellent

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 1234 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact1234 DOIs
2

Add abstracts to 658 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact658 DOIs
3

Deposit reference lists for 493 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact493 DOIs

DOIs for this ISSN

Showing the top 5 of 3879 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Evaluation on the incidence, mortality and tendency of lung… (10.1111/j.1759-7714.2010.00011.x)
Abstract ORCID
91.94 68
2 Comparisons between the National Comprehensive Cancer Networ… (10.1111/j.1759-7714.2010.00016.x)
Abstract ORCID
77.82 35
3 Epidemiology of lung cancer in China (10.1111/1759-7714.12916)
ORCID
63.94 360
4 Review of aerobic glycolysis and its key enzymes – new targe… (10.1111/1759-7714.12148)
ORCID
60.54 263
5 Esophageal cancer statistics in <scp>C</scp>hina, 2011: Esti… (10.1111/1759-7714.12322)
ORCID
57.31 195
6 Traditional <scp>C</scp>hinese medicine and cancer: History,… (10.1111/1759-7714.12270)
ORCID
56.20 176
7 Transbronchial needle aspiration with or without endobronchi… (10.1111/j.1759-7714.2010.00015.x)
Abstract ORCID
53.96 11
8 Epidemiology of lung cancer in <scp>C</scp>hina (10.1111/1759-7714.12169)
ORCID
53.01 131
9 Resisting resistance to cancer immunotherapy (10.1111/1759-7714.12614)
Abstract ORCID
52.07 10
10 Role of endobronchial ultrasound-guided transbronchial needl… (10.1111/j.1759-7714.2010.00010.x)
Abstract ORCID
52.07 10
11 Circulating <scp>PD</scp>‐<scp>L</scp>1 in <scp>NSCLC</scp>… (10.1111/1759-7714.12247)
ORCID
51.03 109
12 Traffic‐related air pollution and lung cancer: A meta‐analys… (10.1111/1759-7714.12185)
ORCID
49.44 94
13 <scp>HMGA</scp>2 regulates lung cancer proliferation and met… (10.1111/1759-7714.12476)
ORCID
48.11 83
14 Tumor suppressive roles of eugenol in human lung cancer cell… (10.1111/1759-7714.12508)
ORCID
47.98 82
15 Preliminary recommendations for lung surgery during <scp>COV… (10.1111/1759-7714.13423)
Abstract ORCID
47.71 8
16 Intensity modulated radiation therapy in the treatment of es… (10.1111/j.1759-7714.2010.00017.x)
Abstract ORCID
47.71 8
17 Combination of platelet to lymphocyte ratio and neutrophil t… (10.1111/1759-7714.12178)
ORCID
47.44 78
18 Incidence and management of chylothorax after esophagectomy (10.1111/1759-7714.12240)
ORCID
47.44 78
19 Role of acetylcholinesterase in lung cancer (10.1111/1759-7714.12249)
ORCID
47.44 78
20 Multi‐slice computed tomography characteristics of solitary… (10.1111/1759-7714.12280)
ORCID
46.13 69
21 Roles of miR‐182 in sensory organ development and cancer (10.1111/1759-7714.12164)
ORCID
45.32 64
22 Cardiopulmonary exercise testing screening and pre‐operative… (10.1111/1759-7714.12199)
ORCID
45.32 64
23 Esophageal cancer complicated by esophagopulmonary fistula a… (10.1111/1759-7714.12118)
Abstract ORCID
45.15 7
24 Progress in therapeutic strategies based on cancer lipid met… (10.1111/1759-7714.13146)
Abstract ORCID
45.15 7
25 Review of the role of EBUS-TBNA for the pulmonologist, inclu… (10.1111/j.1759-7714.2010.00007.x)
Abstract ORCID
45.15 7
26 Apolipoprotein C1 (<scp>APOC</scp>1) as a novel diagnostic a… (10.1111/1759-7714.12117)
ORCID
44.98 62
27 Evaluation of a novel saliva‐based epidermal growth factor r… (10.1111/1759-7714.12350)
ORCID
44.27 58
28 Integrated micro<scp>RNA</scp> and gene expression profiling… (10.1111/1759-7714.12467)
ORCID
42.69 50
29 Increased hepcidin expression in non‐small cell lung cancer… (10.1111/1759-7714.12046)
ORCID
42.47 49
30 Lung cancer incidence and mortality in <scp>C</scp>hina, 201… (10.1111/1759-7714.12286)
ORCID
42.47 49
31 Elevated pretreatment <scp>n</scp>eutrophil/<scp>w</scp>hite… (10.1111/1759-7714.12454)
ORCID
42.47 49
32 Impact of pulmonary rehabilitation on postoperative complica… (10.1111/1759-7714.12466)
ORCID
42.25 48
33 Safety and efficacy of tislelizumab plus chemotherapy for fi… (10.1111/1759-7714.13690)
Abstract ORCID
42.25 6
34 Autonomic nervous infiltration positively correlates with pa… (10.1111/1759-7714.12374)
ORCID
42.03 47
35 CircAGFG1 sponges miR‐203 to promote EMT and metastasis of n… (10.1111/1759-7714.13131)
ORCID
42.03 47
36 <scp>C</scp>hina national lung cancer screening guideline wi… (10.1111/1759-7714.12287)
ORCID
41.80 46
37 Bayesian age‐period‐cohort prediction of lung cancer inciden… (10.1111/j.1759-7714.2011.00062.x)
ORCID
41.57 45
38 Tissue‐specific and plasma microRNA profiles could be promis… (10.1111/1759-7714.12317)
ORCID
41.09 43
39 Circulating long non‐coding <scp>HOX</scp> transcript antise… (10.1111/1759-7714.12373)
ORCID
41.09 43
40 Female breast cancer incidence and mortality in <scp>C</scp>… (10.1111/1759-7714.12426)
ORCID
41.09 43
41 Risk factors associated with treatment refusal in lung cance… (10.1111/1759-7714.12461)
ORCID
41.09 43
42 Demonstration program of population‐based lung cancer screen… (10.1111/1759-7714.12078)
ORCID
40.84 42
43 MiR‐155 inhibits proliferation and invasion by directly targ… (10.1111/1759-7714.12492)
ORCID
40.84 42
44 Prevalence of ROS1 fusion in Chinese patients with non‐small… (10.1111/1759-7714.12899)
ORCID
40.84 42
45 Activating transcription factor 3 promotes malignance of lun… (10.1111/1759-7714.12421)
ORCID
40.58 41
46 Efficacy of prednisone for prevention of esophageal strictur… (10.1111/1759-7714.12473)
ORCID
40.58 41
47 Early detection of lung cancer: Low‐dose computed tomography… (10.1111/1759-7714.12253)
ORCID
40.32 40
48 Pretreatment hematological markers predict clinical outcome… (10.1111/1759-7714.12815)
ORCID
40.32 40
49 Long‐term results of a randomized, double‐blind, and placebo… (10.1111/1759-7714.12050)
ORCID
40.05 39
50 Axillary lymph node metastasis detection by magnetic resonan… (10.1111/1759-7714.12774)
ORCID
39.78 38